Rubicon

[Xerof]

Not exactly, not in their own right.

"Conditional power to control the disposal of the financial product. The relevant interest arises only from the powers of investment contained in an investment management contract for Bank of New Zealand’s portfolio execution service"

Perhaps that yank who bought the 25m last week has some sort of portfolio management agreement with BNZ.

[Balance]

http://nzx-prod-s7fsd7f98s.s3-websit...995/272991.pdf


Good summary :

It is a global leader in advanced forestry genetics, operating in the world’s major commercial tree species
(pine and eucalyptus), in geographies with high annual planting rates (Brazil, the US, and Australasia). It sells to major forestry players in thosecountries, and has a leading market position in its largest
commercial market, the US.

It has a pre-eminent intellectual property position, which includes an industry- leading germplasm repository (i.e. genetic library), a proprietary ‘tree machine’ platform, an extensive database of global trials, varietal and transgenic technology, and a genomics platform - all protected by a patent portfolio and a ‘bank’ of trade secrets.

It has a portfolio of advanced products that do not require regulatory approval, which are currently being commercialised.

In its last fiscal year, ArborGen turned EBITDA positive, and its forecasts are for it to be cash- positive from now onwards.

The considerable investment in research, capability and customer preparation has been made. ArborGen
is now all about commercialising that investment by converting its customers to its advanced genetics products.

[dubya]

Just attended special shareholders meeting. Still there having a coffee.

The gist of the questions asked of the chairman and his answers (which may or may not be publicly available) were:

1. No dividends for 2 to 3 years as cash needed for capital requirements.
2. Name will probably be changed from Rubicon to Arborgen.
3. Listing on the US market is the appropriate path forward. (With listing remaining on NZ board)

[Balance]

Just attended special shareholders meeting. Still there having a coffee.

The gist of the questions asked of the chairman and his answers (which may or may not be publicly available) were:

1. No dividends for 2 to 3 years as cash needed for capital requirements.
2. Name will probably be changed from Rubicon to Arborgen.
3. Listing on the US market is the appropriate path forward. (With listing remaining on NZ board)

Thanks, dubya.

Was going to attend but could not make it.

Try and have a one on one with Moriarty - he can be persuaded to disclose what he thinks Arborgen will eventually be worth.

[dubya]

Sorry but I've already left.

[dodgy]

Sorry but already left.

Hi
Did the motion pass?
Thanks
-dodgy

[dubya]

Still don't know how to answer with the quote in my reply. Sorry.

They didn't announce anything during the meeting. Some people cast their votes at the very end do I guess they're still counting them. I'd assume it will be announced this afternoon.

[winner69]

http://nzx-prod-s7fsd7f98s.s3-websit...995/272991.pdf


Good summary :

It is a global leader in advanced forestry genetics, operating in the world’s major commercial tree species
(pine and eucalyptus), in geographies with high annual planting rates (Brazil, the US, and Australasia). It sells to major forestry players in thosecountries, and has a leading market position in its largest
commercial market, the US.

It has a pre-eminent intellectual property position, which includes an industry- leading germplasm repository (i.e. genetic library), a proprietary ‘tree machine’ platform, an extensive database of global trials, varietal and transgenic technology, and a genomics platform - all protected by a patent portfolio and a ‘bank’ of trade secrets.

It has a portfolio of advanced products that do not require regulatory approval, which are currently being commercialised.

In its last fiscal year, ArborGen turned EBITDA positive, and its forecasts are for it to be cash- positive from now onwards.

The considerable investment in research, capability and customer preparation has been made. ArborGen
is now all about commercialising that investment by converting its customers to its advanced genetics products.

David Darling should be proud of what he created imany years ago eh

[Balance]

David Darling should be proud of what he created imany years ago eh

Haha - many decades from now, there may be light at the end of the tunnel for PEB too?

Proviso being that he can keep the equity raisings going beyond 2018.

[winner69]

Haha - many decades from now, there may be light at the end of the tunnel for PEB too?

Proviso being that he can keep the equity raisings going beyond 2018.

Arbogen still on his CV